TCT-422 Trends and Outcomes of Antegrade Dissection and Re-Entry in Chronic Total Occlusion Percutaneous Coronary Intervention

Document Type

Conference Proceeding

Publication Date

10-24-2023

Publication Title

J Am Coll Cardiol

Keywords

adult, chronic total occlusion, comorbidity, conference abstract, controlled study, dissection, female, human, incidence, major adverse cardiac event, major clinical study, male, outcome assessment, percutaneous coronary intervention, prevalence, risk assessment, surgery

Abstract

Background: The contemporary frequency and outcomes of antegrade dissection and re-entry (ADR) for chronic total occlusion (CTO) percutaneous coronary intervention (PCI) have received limited study. Methods: We examined the clinical and angiographic characteristics and procedural outcomes of 12,568 patients who underwent 12,841 CTO PCIs performed at 46 U.S. and non-U.S. centers between 2012 and 2023. Results: ADR was used in 2,385 (18.6%) of the procedures. ADR use declined from 37.9% in 2012 to 14.5% in 2022 (P < 0.001). Patients in whom ADR was used had a higher prevalence of comorbidities. CTOs treated with ADR were more likely to have complex angiographic characteristics and had higher mean J-CTO score (2.94 ± 1.11 vs 2.23 ± 1.26; P < 0.001). ADR cases had lower technical success (77.0% vs 89.3%; P < 0.001), and higher incidence of in-hospital major adverse cardiac events (MACE) (3.7% vs 1.6%; P < 0.001). The use of CrossBoss declined from 71% in 2012 to 1.4% in 2022 and was associated with higher technical success (87%) compared with wire-based techniques (73%). The Stingray device displayed higher technical success (86%) compared with subintimal tracking and re-entry (STAR) (74%) and limited antegrade subintimal tracking (LAST) (78%); however, its use has been decreasing, with STAR becoming the most used re-entry technique in 2022 (44% STAR vs 38% Stingray). [Formula presented] Conclusion: The use of ADR has been decreasing. ADR was used in more complex lesions and was associated with lower technical success and higher MACE, compared with non-ADR cases. There has been a decrease in Stingray use and an increase in the use of STAR for re-entry. Categories: CORONARY: Complex and Higher Risk Procedures for Indicated Patients (CHIP)

Volume

82

Issue

17 Suppl

First Page

B169-B170

This document is currently not available here.

Share

COinS